Tuesday, July 03, 2018 10:06:13 PM
Until now, everything about Anavex Life Science Corp and it’s untested drugs was stated or regarded with words such as “Perhaps.”
“Perhaps Anavex 2-73 might yield some unique, helpful CNS disease outcomes. But no way to know yet.”
“Perhaps the molecule does, indeed, re-connect neuron organelles, allowing the restoration of normalized function. But not known with any certainty.”
“Perhaps Anavex 2-73 will be therapeutic for Alzheimer’s patients. But no way to know that without a proper, large-number double-blind clinical test.”
Now, statements about Anavex Life Sciences Corp and its drug Anavex 2-73 will no longer include the words “perhaps” or “maybe.”
The conduct of a large-scale, double-blind clinical trial, authorized and monitored by a modern nation’s medical control agency (in Australia) removes a lot of “maybe’s.” Anavex skeptics can express each of their previous cautions and warnings about the company and the drug’s insufficiencies and information gaps. But many of those are no longer valid.
A 48 week clinical trial, double-blind and placebo-controlled, is the gold standard of clinical drug trials. No one, pro or con, will be able to persuasively argue against whatever results appear from the trial.
The mere fact that Australian medical authorities have authorized and will monitor the trial is extremely affirmative. They don’t have any “concerns” or mis-givings about either the drug itself, nor the conduct of the new trial. They’ve given the go-ahead; pulling the air out of the so-often posted statements, here, of inadequacies of multiple kinds.
In short, Anavex Life Sciences Corp, and Anavex 2-73 are legitimate; not conjectural, “maybe” or “perhaps” entities any more. Anavex is now playing on the big stage, with a full script, with the best critics in the opening night audience. The program tells the unfolding story: The new drug Anavex 2-73 will be precisely tested on precisely selected Alzheimer’s patients who have the highest chances of gaining degrees of symptomatic relief. 450 actors, in three concurrent acts. On stage left, those getting a low dose of the drug. On center stage, actors getting a high dose. On stage right, those getting a starch pill that looks and tastes like the real pills the other actors are getting.
Come Thursday morning, who will be at the box office clamoring for tickets? Surely, a bunch of back of the house retail types; those who have been following the Anavex story, but awaiting “real news.” They have it, now.
But shoving their ways to the front of the lines will be investment fund managers, and higher-ups in pharmaceutical companies. Both will be greatly affected by how the play ends, how the plot turns out.
Will be fun watching how the investment and pharmaceutical press communities tell the new Anavex story. “Perhaps” will be replaced with “Will be closely watched....”
Most of us, here, have our tickets (well, AVXL shares). Will be one of the best stage shows in a long time.
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM